Though it was hypothesized that dual HER2 blockade, by eliciting additional inhibition of HER2 signaling, could increase the cardiotoxicity of HER2-positive BC treatment compared with trastuzumab alone, this has never been demonstrated in diverse clinical trials and meta-analyses [4,15,16,17]. Here, ERBB2 is linked to breast cancer.